Omeprazole Delayed Release (DR) Capsules Bioequivalence S... | NCT01170182

Studies
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition

NCT01170182

Sponsor

Dr. Reddy's Laboratories Limited

Status

Completed

Last Update Posted

Jul 27, 2010Estimated

Enrollment

54Actual

Phase

Phase 1

Conditions

Healthy

Interventions

Omeprazole
Prilosec® 40 mg

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2010

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 2006

Primary Completion Date

Apr 2006Actual

Completion Date

Apr 2006Actual

First Submitted Date

May 31, 2010

First Submission Date that Met QC Criteria

Jul 26, 2010

First Posted Date

Jul 27, 2010Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jul 26, 2010

Last Update Posted Date

Jul 27, 2010Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

This study examines the bioequivalence of Dr. Reddy's Omeprazole delayed release capsules under fed condition.

Detailed Description

This is a randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study to compare Omeprazole 40 mg Delayed Release Capsules (Dr. Reddy's Laboratories Ltd.,) with Prilosec® 40 mg (Omeprazole Delayed Release Capsules) (manufactured by Merck & Co., Inc., USA) in 54 healthy, adult, human subjects under fed conditions.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

54Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Omeprazole	Experimental	Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited	Drug: Omeprazole
Prilosec	Active Comparator	Prilosec® 40 mg Merck & Co. Inc	Device: Prilosec® 40 mg

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Omeprazole	Drug	Omeprazole Delayed Release Capsules 40 mg	Omeprazole

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Bioequivalence based on Cmax and AUC parameters		4 months

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Subjects who provided written informed consent.
Subjects who were healthy within 18-45 years of age, weighing at least 50 kg.
Body mass index of ≥18 kglm2 and ≤ 25 kg/m2, with body weight not less than 50 kg.
Subjects with normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the study (dosing in period-I).
Subjects with normal ECG, chest X-ray (PA view) and vital signs.
Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.

Accepts Healthy Volunteers

Yes

Sex

Male

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

45 Years

Standard Ages

Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Manoj K Bose, Dr.	Vimta Labs Limited, 142, IDA, Phase-II, Cherlapally, Hyderabad, India-500 051	Principal Investigator

Locations

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D009853	Omeprazole

Ancestor Terms

ID	Term
D053799	2-Pyridinylmethylsulfinylbenzimidazoles
D013454	Sulfoxides
D013457	Sulfur Compounds
D009930	Organic Chemicals

Browse Leaves

Not provided

Browse Branches

Not provided